Abstract
To verify the role of specific pathways activated by dystrophin absence and to identify potential pharmacotherapies against Duchenne muscular dystrophy we chronically treated (4–8weeks) exercised mdx mice with drugs acting on different targets. We first compared the phosphodiesterases inhibitor pentoxifylline (PTX; 50mg/kg/day i.p.), a wide anti-inflammatory, anti-ischemic and anti-fibrotic drug, with a potentially clinical relevant association: α-methyl-prednisolone (PDN; 1mg/kg/day i.p.) and taurine (1g/kg/day orally), to target inflammatory pathways and calcium homeostasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
